Financial Analysts Roundtable: Medicare Part D, Big Pharma Diversification And The Outlook For M&A
Executive Summary
Three large cap pharmaceutical analysts sat down with "The Pink Sheet" in January to discuss the outlook for the drug industry in 2007. Below are excerpts from a conversation with Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. In the second part of the series, slated to appear in the Feb. 12 issue, the analysts discuss the impact of the changes on Capitol Hill and the regulatory climate.